Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision was bumped from v3.5.2 to v3.5.3, updating the page's metadata.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.1%

- Check53 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page footer.SummaryDifference0.1%

- Check88 days agoChange DetectedUpdated the page to Revision 3.4.2. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check95 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH open status. Updated the site revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.